

"We can expect more approvals of generic favipiravir in India"- Prashant Khadayate

25 June 2020 | Views | By Manbeena Chawla

Prashant Khadayate, Pharma Analyst, GlobalData, Hyderabad is of the view that Favipiravir approval in India will benefit majority of COVID-19 patients



"During this COVID-19 outbreak, each country is making decisions in line with its own public health requirements. We can expect more approvals of generic favipiravir in India. It will also increase drug access and make the pricing competitive. Moreover, the majority of the COVID-19 patients fall in mild to moderate stage and favipiravir can be termed as a drug for the masses amid the COVID-19 outbreak."

Prashant Khadayate, Pharma Analyst, GlobalData, Hyderabad